#Healthcare professionals can now watch recordings from the recent expert-led BeiGeneius Summit on relapsed/refractory chronic lymphocytic leukemia ( #CLL ) and indolent lymphomas. Click here to watch: bit.ly/4b21b9Y

We're pleased to welcome Kimberly Wolf as SVP, Global Commercial Strategy & Operations. Kimberly brings a wealth of expertise, having successfully led teams across hematology/oncology, cell therapy and other areas to help patients around the world. bit.ly/442naeQ

Today marks #Waldenstrom 's Macroglobulinemia World Awareness Day. At BeiGene, we’re committed to supporting patients battling #BloodCancers , including #WM through innovative treatments and shining a spotlight on #WM WorldAwarenessDay to spread knowledge and encourage support.

Head of Market Access Europe, Cathrin Schäfer joined leaders from across the industry today at Reuters Events Pharma 2024 to discuss #HealthEquity challenges and how we can close the access gap around the world. #REPharma2024

Targeted degraders like our CDACs harness a natural process to get rid of disease-causing proteins. This new #DrugDiscovery mechanism potentially side-steps #oncology drug resistance. Visit bit.ly/3xxmjXn to see how we’re developing our investigational BTK-targeted CDAC.

At BeiGene, we are committed to supporting the communities where we live and work. Last year, our colleagues logged over 20,000 volunteer hours across the company. This #NationalVolunteerMonth , we've once again set a goal of 10,000 hours in 2024 and are already making an impact.

#AACR2024 is off to a great start, and our team is excited to be sharing our #science and connecting with #oncology researchers from around the world.

Javad Shahidi, SVP and Head of Biotech Unit shares his perspective. Find BeiGene onsite here: bit.ly/3TNdOi7

We’re in San Diego for #AACR2024 – excited to share our data and join the inspiring conversations about how emerging science holds the potential to change the future of #cancer care. Visit our posters Monday and Tuesday: bit.ly/3TNdOi7

Globally, #EsophagealCancer is the sixth most common cause of #cancer -related deaths. In honor of Esophageal Cancer Awareness Month this month, we spoke with our patient Richard, who shared his diagnosis and how he found strength in support from loved ones and the community.

Check out BeiGene’s CMO Mehrdad Mobasher, as he highlights our latest efficacy analysis for the BTKi landscape in #CLL in a new FiercePharma article: bit.ly/3TGsEqL. #BloodCancer

In honor of #WHM2024 and as part of our commitment to empowering women, we hosted the BeiGene Global Women's Summit w/ the theme “Women Supporting Each Other – Facing the Challenges of the 21st Century.” Thanks to all who came together to make the Summit a meaningful gathering!

#NewData published in Blood Advances highlights the safety profile of our BTK inhibitor related to cardiac events in B-cell malignancies like #CLL . Learn more: bit.ly/4a7COrq

Our ED, Patient Advocacy & Public Health Policy, Maia Thrift Perry recently joined The Max Foundation's Think Tank event and 2024 Gala. Hear from Maia on how our patients-first value drives our partnership with Max to provide #CLL patients in 29 LMICs access to our innovative medicine.

What if we could eliminate selected disease-causing proteins? Targeted degraders are designed to do just that. Visit bit.ly/4a7jIBU to see how we’re developing our investigational BTK-targeted CDAC.

#News for #Investors and #Media : We’re pleased to announce our BTK inhibitor has been approved in Egypt for the treatment of adult patients with #WM , #MZL , and #CLL or #SLL .

#News for #Investors and #Media : We’re proud to share our BTK inhibitor has been approved in Brazil for the treatment of adult patients with treatment-naïve or relapsed/refractory #CLL / #SLL . This approval marks the 4th indication of our treatment for #bloodcancer in the country.

Our investigational BCL2 inhibitor, sonrotoclax, was recently granted Fast Track designation by the U.S. FDA for relapsed/refractory mantle cell #lymphoma after chemoimmunotherapy and a BTK inhibitor. We’re leading with science to advance new #oncology medicines for patients.

#News for #Investors and #Media :  New data about our PD-1 inhibitor in #NSCLC will be presented at the European Lung Cancer Congress 2024. bit.ly/3VrRg9c

#ELCC24 #ESMO

We are proud to share Fast Company has named us one of the Most Innovative Companies of 2024, recognizing our accomplishments in developing and delivering innovative medicines for patients with #cancer across the globe.

Learn more: bit.ly/4ajaoKH #FCMostInnovative

At FiercePharma’s BD&L Summit, our SVP, Corporate Development & Strategy, Jason Radford joined a panel discussion on the current environment and drivers of partnership in pharma. Hear from Jason on how our patient-centric vision guides our approach to #BusinessDevelopment .